Adagio(US:IVVD) Globenewswire·2025-05-23 11:01Core Insights - Invivyd, Inc. announced that its investigational monoclonal antibody PEMGARDA (pemivibart) has been included in the NCCN Clinical Practice Guidelines for B-Cell Lymphomas, recognizing its potential for pre-exposure prophylaxis against COVID-19 in immunocompromised patients [1][2][3] Group 1: Product Development and Approval - PEMGARDA is recognized as a potential option for pre-exposure prophylaxis against COVID-19 in patients with B-cell malignancies, particularly those who may not respond adequately to vaccination [2][3] - The monoclonal antibody is engineered to retain activity against circulating SARS-CoV-2 variants and is currently authorized under Emergency Use Authorization (EUA) from the U.S. FDA for certain patients [3][6] - The NCCN's recommendation is based on the unmet need in patients with B-cell lymphomas, who are at elevated risk for COVID-19-related complications [3][4] Group 2: Clinical Implications - The inclusion of PEMGARDA in the NCCN Guidelines provides clinicians with a valuable tool to protect vulnerable patients from COVID-19, allowing them to continue their cancer care [3][4] - The updated NCCN Guidelines reflect growing clinical and real-world evidence supporting the use of passive immunization to complement vaccination strategies in high-risk oncology populations [4] Group 3: Company Overview - Invivyd, Inc. is a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, starting with SARS-CoV-2 [13] - The company utilizes a proprietary integrated technology platform designed to assess, monitor, develop, and adapt to create best-in-class antibodies [13]